# Tyrolpath

> Tyrolpath is a VC fund backing Biotechnology and Health Diagnostics. See 1 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Total investments: 1
- Last investment: Mar 2022
- Lead investor: 0%
- Last updated: Aug 2026

Tyrolpath is a VC fund focused on Biotechnology and Health Diagnostics. Tyrolpath Obrist Brunhuber operates a pathology and laboratory service that conducts medical testing and analysis for healthcare providers. The organization processes biological samples, delivers diagnostic information, and manages logistics for specimen transport. It collaborates with medical institutions to support clinical diagnostics andquality‑controlled laboratory procedures.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 1 | 100% |
| Health Diagnostics | 1 | 100% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Sola Diagnostics | Product: Sola Diagnostics’ WID®-easy test is a non-invasive epigenetic solution for detecting endometrial cancer in women with abnormal uterine bleeding. By analyzing DNA methylation markers from a simple vaginal swab, it offers high accuracy, reducing false positives and unnecessary surgeries. Target Audience: Designed for gynecologists andhealthcare providers, WID®-easy streamlines diagnostics, cutting costs and false alarms. Women benefit from a painless, accessible test that ensures earlier and more precise detection. Technology: Powered by advanced DNA methylation research, WID®-easy identifies cancer-specific epigenetic markers. With PCR-based analysis and robust clinical validation, it delivers fast, reliable results that integrate seamlessly into medical workflows. Market Positioning: WID®-easy fills a critical gap as a first-line diagnostic for abnormal uterine bleeding. Its clinical validation, accuracy, and cost-efficiency set it apart from invasive procedures. Its ease of use and scalability position it for widespread adoption. Milestones: Sola Diagnostics launched in Austria and Switzerland in 2024 and expanded to Great Britain in 2025. UKCA Marking was registered in December 2024. So far, private equity investments totaling €2.4M have supported Sola's mission to revolutionize women’s health diagnostics. | $1.5M | Seed | Mar 11, 2022 |  |

1 of 1 investments shown.

## Co-investors
- [FPS-Holding](https://shizune.co/investors/profile/fps-holding) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Tyrolpath invest in?

Tyrolpath invests primarily in Biotechnology and Health Diagnostics startups, most often at Seed stage. Most of the 1 investments tracked by Shizune back companies in Austria. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Tyrolpath last invest?

The most recent investment recorded for Tyrolpath closed in Mar 2022. Shizune tracks 1 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co